• Journal of the Korean Society for information Management
• /
• v.38 no.4
• /
• pp.113-128
• /
• 2021

In this study, we aimed to understand the public opinion on COVID-19 vaccine. To achieve the goal, we analyzed COVID-19 vaccine-related Twitter posts. 45,413 tweets posted from March 16, 2020 to March 15, 2021 including COVID-19 vaccine names as keywords were collected. The 12 vaccine names used for data collection included 'Pfizer', 'AstraZeneca', 'Modena', 'Jansen', 'NovaVax', 'Sinopharm', 'SinoVac', 'Sputnik V', 'Bharat', 'KhanSino', 'Chumakov', and 'VECTOR' in the order of the number of collected posts. The collected posts were analyzed manually and automatedly through keyword analysis, sentiment analysis, and topic modeling to understand the opinions for the investigated vaccines. According to the results, there were generally more negative posts about vaccines than positive posts. Anxiety about the aftereffects of vaccination and distrust in the efficacy of vaccines were identified as major negative factors for vaccines. On the contrary, the anticipation for the suppression of the spread of coronavirus following vaccination was identified as a positive social factor for vaccines. Different from previous studies that investigated opinions about COVID-19 vaccines through mass media data such as news articles, this study explores opinions of social media users using keyword analysis, sentiment analysis, and topic modeling. In addition, the results of this study can be used by governmental institutions for making policies to promote vaccination reflecting the social atmosphere.

• Tuberculosis and Respiratory Diseases
• /
• v.57 no.2
• /
• pp.160-168
• /
• 2004

Background : The role of second-line chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC) is known to be limited. Recently, ZD1839, the small molecule epidermal growth factor receptor-tyrosine kinase inhibitor, has been developed and has shown anti-tumor activity in patients with solid malignant tumors including lung cancer. We evaluated the response rate and toxicities of ZD1839 in patients with advanced NSCLC which has progressed after previous chemotherapy. Patients and Methods : We examined 83 patients with advanced NSCLC treated with ZD1839 for more than 1 month in Korea Cancer Center Hospital during the period from January 2002 to September 2003. All the patients were enrolled in the international expanded access program (EAP) with ZD1839 by AstraZeneca. The administered dose of ZD1839 was 250 mg once daily. Chest radiography and laboratory tests were followed-up. We evaluated the response rate, median survival, and toxicity after treatment. Results : Median age of the patients was 59 years (range 33-76). The most predominant cell type was adenocarcinoma and the most stage of the patients was IV. ECOG performance status was as follows; grade 0-1 in 10, grade 2 in 42, and grade 3 in 31 patients. Partial response was achieved in 12 patients (14.5%). Median overall survival was 9.2 (range 1.3-21.6+) months and median time to progression was 3.1 (range 1-21.2+) months. The most common adverse effect of ZD1839 was skin eruption which developed in 25 patients (25.8%). Significantly higher response rate and survival was found in patients with adenocarcinoma or good performance status. Conclusion : ZD1839 showed modest activity and tolerable toxicity in the treatment for patients with NSCLC which has progressed after previous chemotherapy.